JUST over 20% of Australians or 4.9 million people suffer from migraines, with 71% of those migraine sufferers being women and 86% being of working age, according to the Australasian College of Pharmacy.
While a migraine is not life-threatening, it is associated with significant impact on quality of life.
Attacks often disrupt normal life, and impact the ability to work, study and maintain healthy relationships.
The College stated that triptans are a class of medications that have transformed the management of migraines.
From 01 Feb 2021, eletriptan, rizatriptan, sumatriptan and zolmitriptan can be supplied to patients as a Schedule 3 medicine for the acute relief of migraine.
However, triptans are not appropriate for all people living with migraines, and the choice to use them should consider patient and symptom factors, the College stressed, adding that it has launched a module to provide an update on the complexities of migraine management.
The module also provides pharmacists with useful information to confidently manage a Schedule 3 request for these medications.
The Australasian College of Pharmacy and their partner GuildEd would like to acknowledge Viatris' financial support and subject matter expertise in developing this module.
To enrol in this migraine-medication course, CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 May 23
